Neurocrine Biosciences | NBIX - Ebitda



Neurocrine Biosciences reported $152.9M in EBITDA for its fiscal quarter ending in June of 2025.


Ebitda Change Date
AbbVie USD 4.4B 2.52B Mar/2025
Acadia Pharmaceuticals USD 35.31M 13.07M Jun/2025
Agios Pharmaceuticals USD -125797000 20.45M Jun/2025
ALKERMES USD 126.53M 105.32M Jun/2025
Alnylam Pharmaceuticals USD 18.83M 13.65M Jun/2025
Amgen USD 3.6B 147M Jun/2025
Biogen USD 1.01B 456.5M Jun/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Cytokinetics USD -153331000 16.67M Mar/2025
Dynavax Technologies USD -21594000 22.03M Mar/2025
Exelixis USD 220.92M 26.71M Jun/2025
Gilead Sciences USD 3.4B 797M Jun/2025
Halozyme Therapeutics USD 225.5M 63.51M Jun/2025
Incyte USD 581.52M 358.87M Jun/2025
Ionis Pharmaceuticals USD 150.23M 291.7M Jun/2025
Neurocrine Biosciences USD 152.9M 121.6M Jun/2025
Pfizer USD 5.32B 889M Jun/2025
Prothena USD -51782000 12.89M Jun/2025
Regeneron Pharmaceuticals USD 1.66B 926.5M Jun/2025
Repligen USD 32.18M 9.36M Jun/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Teva Pharmaceutical Industries USD 1.23B 124M Jun/2025
Ultragenyx Pharmaceutical USD -91344000 35.09M Jun/2025
Vertex Pharmaceuticals USD 1.34B 556.6M Jun/2025